Plasma 1,25-Dihydroxyvitamin D Levels in Patients Receiving Anticonvulsant Drugs
- 1 April 1977
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 44 (4) , 617-621
- https://doi.org/10.1210/jcem-44-4-617
Abstract
Recent evidence has linked altered plasma vitamin D metabolite levels to the reported occurrence of hypocalcemia and other metabolic abnormalities in patients receiving anticonvulsant drugs. We have measured plasma levels of 25- hydroxyvitamin D (25-(OH)D) and 1,25-dihydroxyvitamin D (1,25-(OH)2D) in institutionalized patients on diphenylhydantoin (Dilantin) and/or phenobarbital therapy. Values were compared with those obtained in institutionalized patients receiving no drugs and with normal ambulatory subjects. Although plasma 25-(OH)D levels were lower in the patients on drugs, a deficiency of 1,25-(OH)2D, the tissue active metabolite of vitamin D, was not present. These results indicate that in patients taking anticonvulsant drugs, the serum calcium, phosphorus, alkaline phosphatase and parathyroid hormone (PTH) abnormalities are not caused by a defective formation of 1,25-(OH)2D.Keywords
This publication has 4 references indexed in Scilit:
- 1,25-Dihydroxyvitamin D in Biological Fluids: A Simplified and Sensitive AssayScience, 1976
- Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3.Journal of Clinical Investigation, 1976
- Diphenylhydantoin: direct inhibition of the vitamin D3-mediated calcium absorptive mechanism in organ-cultured duodenumBiochemical Pharmacology, 1976
- Radiologic Bone Changes and Hypocalcemia with Anticonvulsant Therapy in EpilepsyAnnals of Internal Medicine, 1972